02015nas a2200397   4500000000100000008004100001260001300042653001500055653001000070653001100080653001600091653001200107653003000119653001600149653001100165653001100176653002300187653001200210653000900222653003800231653002300269653001700292653001800309653001300327653002100340100001600361700001600377700001400393700001800407245013700425856004100562300001100603490000700614520098200621022001401603       1987                            d  c1987 Sep10aAdolescent10aAdult10aBrazil10aClofazimine10aDapsone10aDrug Therapy, Combination10aEthionamide10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aPatient Acceptance of Health Care10aPatient Compliance10aPrednisolone10aProthionamide10aRifampin10aUrban Population1 aAndrade V L1 aMarques A B1 aCunha L H1 aAvelleira J R00aFeasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.  uhttp://ila.ilsl.br/pdfs/v55n3a02.pdf  a435-400 v553 a<p>The acceptance of the WHO regimen in a group of 220 patients was approximately 84.5%. Only 11% abandoned the treatment, and the substitution of ethionamide or prothionamide for clofazimine due to excessive hyperpigmentation was necessary in only eight cases. The WHO regimens adopted provided a more frequent (monthly) relationship between the patients and their health service. It was necessary to: a) reorganize the technical-administrative infrastructure, with the intention of providing an improved service to the patients for treatment and control; and b) pay more attention to the problem of deformities and health education activities. As for the side effects of the drugs, 54 patients showed alterations in their liver function tests, which were usually mild and which resolved despite continuation of the treatment. Of the reactional episodes observed during MDT, it would not appear that the therapeutic regimens contributed to their occurrence or aggravation.</p>  a0148-916X